Amylyx’s drug, a powder that has been going by the designation AMX0035, combines two separate medicines. Each strikes a different line of attack that ALS takes to destroy the motor neurons in patients.
The CENTAUR study is not accepting new participants. To be introduced with study teams for ALS trials that are currently active, please fill out the interest form below.
More than 16,000 Americans have ALS, which kills off the nerve cells that control muscle movements. As these motor neurons die, patients lose the ability to eat, speak, move and breathe. Within three to five years of symptoms, most patients die.
Only two drugs have been approved to treat the underlying cause of the disease, and neither provides a cure.
Dr. Sabrina Paganoni from Massachusetts General Hospital discusses CENTAUR, a phase 2 trial for people with ALS.
In the CENTAUR trial, AMX0035 was tested in patients who were diagnosed within 18 months of symptoms appearing and had developed problems like trouble speaking, difficulty walking and arm weakness.
The 137 subjects in the trial took either AMX0035 or a placebo for six months in addition to any other ALS drugs they were taking.
Participants in CENTAUR were given the option after the trial to enroll in an open-label extension study to receive treatment with AMX0035. Nearly 90 percent of participants who completed CENTAUR elected to enroll in the extension study.
Interim data from the ongoing extension study will be presented in 2020.
The CENTAUR-OLE study provides patients with the option of continuing treatment once they have completed the 24-week study period.
The trial will evaluate AMX0035’s ability to have an impact on daily functioning, muscle strength, and respiratory function as well as its ability to alter biological markers of ALS.
To connect with ongoing ALS studies, fill out the interest form, contact +1 (415) 326-8831, or email the Clara Health team at [email protected]